公司資料
Shattuck Labs 股價、新聞與催化劑
- 股票代碼:
- STTK
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
7.39 USD (-0.40%)
收盤價
最後更新: 2026年8月17日
373M USD
市值
股價為何變動
As of Aug 17, 2026, STTK closed down 0.40% at $7.39. No new same-company headline was identified in the current news window.
公司概覽
Immune-Mediated Diseases
Shattuck Labs develops antibodies for inflammatory and immune-mediated diseases. Its current strategy centers on blocking death receptor 3, a regulator of activated immune cells.
SL-325
SL-325 is a monoclonal antibody targeting DR3. The candidate has completed enrollment in a Phase 1 single- and multiple-ascending-dose study and is being prepared for Phase 2 development in Crohn's disease.
DR3 Platform
Shattuck is also exploring bispecific DR3-blocking antibodies and additional indications where excessive DR3 signaling may contribute to chronic inflammation.
未來催化劑
- Comprehensive Phase 1 data for SL-325 in the second quarter of 2026.
- Initiation of a Phase 2 study of SL-325 in Crohn's disease in the third quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。